Paul R. Kirchgraber

Insider Reports History

Location
Burlington, NC
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Paul R. Kirchgraber:

Company Role Class Num Shares Value Price $ Report Date Ownership
LABORATORY CORP OF AMERICA HOLDINGS CEO, Covance Drug Development Common Stock 12,946 $2,841,647 $219.50 19 May 2023 Direct
LABORATORY CORP OF AMERICA HOLDINGS CEO, Covance Drug Development Restricted Stock Unit 3,001 $632,350 $210.71 11 Feb 2023 Direct
LABORATORY CORP OF AMERICA HOLDINGS CEO, Covance Drug Development Non-qualified Stock Options 0 19 May 2023 Direct

Insider Reports Filed by Paul R. Kirchgraber

Symbol Company Period Transactions Value $ Form Type Role Filing Time
LH LABORATORY CORP OF AMERICA HOLDINGS 19 May 2023 3 -$147,914 4 CEO, Covance Drug Development 23 May 2023, 08:06
LH LABORATORY CORP OF AMERICA HOLDINGS 30 Mar 2023 2 -$648,484 4 CEO, Covance Drug Development 03 Apr 2023, 10:13
LH LABORATORY CORP OF AMERICA HOLDINGS 21 Feb 2023 3 -$1,457,145 4 CEO, Covance Drug Development 23 Feb 2023, 08:54
LH LABORATORY CORP OF AMERICA HOLDINGS 11 Feb 2023 3 -$35,234 4 CEO, Covance Drug Development 14 Feb 2023, 13:57
LH LABORATORY CORP OF AMERICA HOLDINGS 07 Feb 2023 2 $0 4 CEO, Covance Drug Development 09 Feb 2023, 11:02
LH LABORATORY CORP OF AMERICA HOLDINGS 04 Feb 2023 3 -$40,098 4 CEO, Covance Drug Development 07 Feb 2023, 13:51
LH LABORATORY CORP OF AMERICA HOLDINGS 02 Feb 2023 3 -$35,954 4 CEO, Covance Drug Development 06 Feb 2023, 14:45
LH LABORATORY CORP OF AMERICA HOLDINGS 01 Nov 2022 3 -$198,524 4 CEO, Covance Drug Development 03 Nov 2022, 17:00
LH LABORATORY CORP OF AMERICA HOLDINGS 27 Mar 2022 2 -$455,540 4 CEO, Covance Drug Development 29 Mar 2022, 12:04
LH LABORATORY CORP OF AMERICA HOLDINGS 11 Feb 2022 5 -$29,449 4 CEO, Covance Drug Development 15 Feb 2022, 15:42
LH LABORATORY CORP OF AMERICA HOLDINGS 04 Feb 2022 3 -$45,784 4 CEO, Covance Drug Development 08 Feb 2022, 10:13
LH LABORATORY CORP OF AMERICA HOLDINGS 02 Feb 2022 3 -$39,338 4 CEO, Covance Drug Development 04 Feb 2022, 08:44
LH LABORATORY CORP OF AMERICA HOLDINGS 01 Nov 2021 3 -$259,324 4 CEO, Covance Drug Development 03 Nov 2021, 11:47
LH LABORATORY CORP OF AMERICA HOLDINGS 06 May 2021 1 -$691,375 4 CEO, Covance Drug Development 10 May 2021, 08:21